血游离轻链与M蛋白检测在膜性肾病合并MGUS患者中的临床意义

doi:10.3760/cma.j.issn.1007-1245.2024.17.015

摘要/Abstract

摘要：

目的　探讨血游离轻链（sFLC）与M蛋白检测在膜性肾病（MN）合并意义未明单克隆免疫球蛋白血症（MGUS）患者中的临床意义。方法　研究采用前瞻性设计，纳入2021年1月至2023年10月在西安交通大学第一附属医院榆林医院诊治的82例MN患者，根据是否合并MGUS分为MN组（53例）和merge组（29例）。merge组男18例、女11例，年龄（52.64±7.33）岁；MN组男33例、女20例，年龄（55.35±6.89）岁。采用血清学检测方法对患者进行sFLC［κ轻链（sFLCκ）、λ轻链（sFLCλ）］与M蛋白检测，并通过logistic回归分析探讨其与MN合并MGUS的关系，并使用受试者操作特征曲线（ROC）检测sFLC联合M蛋白在MN合并MGUS诊断中的性能。统计学方法采用t检验、χ²检验。结果　merge组红细胞沉降率（ESR）、血清肌酐（Scr）、C反应蛋白（CRP）和血尿素氮（BUN）指标均高于MN组［（48.52±5.65）mm/h比（36.34±4.35）mm/h、（84.51±10.26）µmol/L比（72.65±8.25）µmol/L、（2.18±0.64）mg/L比（1.26±0.35）mg/L、（6.45±1.27）mmol/L比（5.12±1.12）mmol/L］，差异均有统计学意义（t=10.884、5.702、8.434、4.902，均P<0.05）。merge组阳性率为96.55%（28/29），高于MN组的3.77%（2/53），差异有统计学意义（χ²=69.543，P<0.05）。merge组sFLCκ水平及sFLCκ/λ比值均高于MN组［（453.51±123.57）mg/L比（62.84±100.25）mg/L、（15.89±2.84）比（1.11±0.26）］，sFLCλ水平低于MN组［（28.54±23.84）mg/L比（56.77±18.35）mg/L］，差异均有统计学意义（t=15.520、37.791、5.979，均P<0.05）。相关性分析结果显示，sFLCκ、sFLCκ/λ比值与肾功能损害及炎症水平有显著相关性，而sFLCλ相关性相对较弱。逻辑回归分析显示，sFLCκ、sFLCκ/λ比值对诊断具有显著影响，而sFLCλ具有负向影响。ROC分析显示，sFLC联合M蛋白进行诊断时，灵敏度为96.6%，特异度为77.4%，约登指数为73.9%，曲线下面积为0.933，95%CI 0.884～0.982。结论　sFLC与M蛋白检测对于MN合并MGUS患者的诊断和疾病活动度评估具有重要临床意义，与肾功能损害程度密切相关，可为监测和治疗效果评估提供重要参考。

关键词:

膜性肾病, 意义未明单克隆免疫球蛋白血症, 血游离轻链, M蛋白

Abstract:

Objective　To explore the clinical significance of serum free light chains (sFLC) and M-protein in patients with membranous nephropathy (MN) and monoclonal gammopathy of undetermined significance (MGUS). Methods　A prospective study design was employed. Eighty-two patients with MN treated at Yulin Hospital, First Hospital, Xi'an Jiaotong University from January 2021 to October 2023 were selected, and were divided into an MN group (53 cases) and a merge group (29 cases) according to whether they were combined with MGUS. There were 18 males and 11 females in the merge group; they were (52.64±7.33) years old. There were 33 males and 20 females in the MN group; they were (55.35±6.89) years old. The serological testing methods were used to detect the sFLC (sFLCκ and sFLCλ) and M-protein in these patients. Logistic regression analysis was used to explore their relationship with MN combined with MGUS, and the receiver operating characteristic curve (ROC) was used to test the diagnostic performance of sFLC combined with M-protein for MN combined with MGUS. t and χ² tests were applied. Results　The erythrocyte sedimentation rate (ESR), serum creatinine (Scr), C-reactive protein (CRP), and blood urea nitrogen (BUN) in the merge group were higher than those in the MN group [(48.52±5.65) mm/h vs. (36.34±4.35) mm/h, (84.51±10.26) µmol/L vs. (72.65±8.25) µmol/L, (2.18±0.64) mg/L vs. (1.26±0.35) mg/L, and (6.45±1.27) mmol/L vs. (5.12±1.12) mmol/L], with statistical differences (t=10.884, 5.702, 8.434, and 4.902; all P<0.05). The positive rate in the merge group was higher than that in the MN group [96.55% (28/29) vs. 3.77% (2/53)], with a statistical difference (χ²=69.543; P<0.05). The level of sFLCκ and sFLCκ/λ ratio in the merge group were higher than those in the MN group [(453.51±123.57) mg/L vs. (62.84±100.25) mg/L and (15.89±2.84) vs. (1.11±0.26)]; the level of sFLCλ in the merge group was lower than that in the MN group [(28.54±23.84) mg/L vs. (56.77±18.35) mg/L]; there were statistical differences (t=15.520, 37.791, and 5.979; all P<0.05). The correlation analysis showed that sFLCκ and sFLCκ/λ ratio were significantly correlated with renal impairment and inflammation level, while sFLCλ had relatively weaker correlation. The logistic regression analysis indicated that sFLCκ and sFLCκ/λ ratio significantly influenced diagnosis, whereas sFLCλ had a negative impact. The ROC analysis demonstrated that sFLC combined with M-protein for the diagnosis had a sensitivity of 96.6%, a specificity of 77.4%, a Youden's index of 73.9%, and an area under the curve (AUC) of 0.933, with a 95% confidence interval (CI) of 0.884 to 0.982. Conclusions　The detection of sFLC and M-protein is of significant clinical importance for the diagnosis and assessment of disease activity in patients with MN and MGUS. They are closely related to the degree of kidney function damage and can serve as important references for monitoring and assessing treatment efficacy.

Key words:

Membranous nephropathy, Monoclonal gammopathy of undetermined significance, Serum free light chains, M-protein

赵辽辽常露元曹丽.

血游离轻链与M蛋白检测在膜性肾病合并MGUS患者中的临床意义 [J]. 国际医药卫生导报, 2024, 30(17): 2894-2899.

Zhao Liaoliao, Chang Luyuan, Cao Li.

Clinical significance of serum free light chains combined with M-protein in patients with membranous nephropathy and monoclonal gammopathy of undetermined significance [J]. International Medicine and Health Guidance News, 2024, 30(17): 2894-2899.

参考文献

[1] Ronco P, Beck L, Debiec H, et al. Membranous nephropathy[J].Nat Rev Dis Primers,2021,7(1):69.DOI:10.1038/s41572-021-00303-z.
[2] 刘源源,曹新冉,苑海涛. 意义未明单克隆免疫球蛋白血症相关的心肌肥厚1例[J]. 老年医学研究,2023,4(4):45-48.DOI:10.3969/j.issn.2096-9058.2023.04.010.
[3] Liu J, Liang D, Liang S, et al. Clinicopathologic characteristics and prognostic analysis of monoclonal gammopathy of renal significance (MGRS) in patients with IgM monoclonal gammopathy: a case series[J].Sci Rep,2022,12(1):16994.DOI:10.1038/s41598-022- 21152-0.
[4] 李超,文煜冰,李航,等. 血游离轻链在有肾脏意义的单克隆免疫球蛋白血症中的诊断价值[J]. 中华医学杂志,2017,97(30):2344-2348.DOI:10.3760/cma.j.issn. 0376-2491.2017.30.006.
[5] Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance[J].Blood,2019,133(23):2484-2494.DOI:10.1182/blood.2019846782.
[6] Couser WG. Primary membranous nephropathy[J].Clin J Am Soc Nephrol,2017,12(6):983-997.DOI:10.2215/CJN.11761116.
[7] 傅琤琤,金松,吴德沛. «中国多发性骨髓瘤诊治指南(2017年修订)»初始治疗部分的解读[J]. 中华内科杂志,2017,56(11):798-799.DOI:10.3760/cma.j.issn. 0578-1426.2017.11.003.
[8] 林孝怡,卢洁,施新明. 95例意义未明的单克隆丙种球蛋白血症实验室特征分析[J]. 检验医学,2020,35(10):1040-1042.DOI:10.3969/j.issn.1673-8640.2020.10.017.
[9] 谢雅琼,林孝怡. 血清游离轻链在鉴别诊断不同病因肾病的应用价值及其与患者肾功能分期的相关性分析[J]. 诊断学理论与实践,2023,22(2):166-171.DOI:10.16150/j.1671-2870.2023.02.010.
[10] 徐双,路瑾,赵磊,等. 血清蛋白电泳识别M蛋白的规则制定及其在健康人群M蛋白筛查中的应用[J]. 检验医学,2020,35(7):668-672.DOI:10.3969/j.issn.1673-8640.2020. 07.009.
[11] 高歌,张鑫越,董奕君,等. 单纯膜性肾病与膜性肾病合并意义未明单克隆免疫球蛋白血症的差异性探讨[J]. 天津医药,2023,51(8):878-882.DOI:10.11958/20221789.
[12] Martín-Nares E, Saavedra-González V, Fagundo-Sierra R, et al. Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease[J].Sci Rep,2021,11(1):1832.DOI:10.1038/s41598-021-81321-5.
[13] Sandfeld-Paulsen B, Aggerholm-Pedersen N, Samson MH, et al. A cohort study of free light chain ratio in combination with serum protein electrophoresis as a first-line test in general practice[J].Cancers (Basel),2022,14(12):2930.DOI:10.3390/cancers14122930.
[14] Pearson DS, McEvoy DS, Murali MR, et al. Use of clinical decision support to improve the laboratory evaluation of monoclonal gammopathies[J].Am J Clin Pathol,2023,159(2):192-204.DOI:10.1093/ajcp/aqac151.
[15] 谢雅琼,林孝怡. 血清游离轻链在鉴别诊断不同病因肾病的应用价值及其与患者肾功能分期的相关性分析[J]. 诊断学理论与实践,2023,22(2):166-171.DOI:10.16150/j.1671-2870.2023.02.010.
[16] Jain A, Haynes R, Kothari J, et al. Pathophysiology and management of monoclonal gammopathy of renal significance[J].Blood Adv,2019,3(15):2409-2423.DOI:10.1182/bloodadvances.2019031914.
[17] Lao KM, Pokharel A, Elzieny MMMI, et al. Defect in automated antigen excess detection discovered after reviewing serum free light chain results in context with clinical findings[J].Lab Med,2024,55(1):106-108.DOI:10.1093/labmed/lmad043.
[18] Tacchetti P, Rocchi S, Zamagni E, et al. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma[J].Am J Hematol,2022,97(12):1607-1615.DOI:10.1002/ajh.26747.
[19] 陈旭端,骆晓峰,祖燕萍,等. 初诊多发性骨髓瘤患者的血清游离轻链对肾功能及预后的影响[J]. 中国实验血液学杂志,2019,27(6):1862-1868.DOI:10.19746/j.cnki.issn1009-2137.2019.06.025.
[20] SAÇKAN F, ÜNAL ALİ. Simultaneous evaluation of serum immunofixation electrophoresis and serum free light chain measurements used in the diagnosis of monoclonal gammopathy and smoldering multiple myeloma of uncertain significance in the presence of risk factors[J]. ACTA ONCOLOGICA TURCICA,2023,56(1).DOI:10.5505/aot.2023.32650.
[21] Azimi V, Slade M, Fiala M, et al. A single reference interval for interpreting serum free light chains across patients with varying renal function[J].Clin Chem,2023,6:hvad043.DOI:10.1093/clinchem/hvad043.
[22] 魏宇君,李新,申曼,等. 肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J]. 中国全科医学,2021,24(18):2359-2363.DOI:10.12114/j.issn.1007-9572.2021.00.410.
[23] 周琳,魏芳. M蛋白阴性POEMS综合征1例[J]. 山西医科大学学报,2023,54(4):561-564.DOI:10.13753/j.issn.1007-6611.2023.04.022.
[24] 冯月英. 轻链型淀粉样变性肾病临床及病理特点分析[D].石家庄:河北医科大学,2019.
[25] 史嘉颖. 血清游离轻链检测在初诊多发性骨髓瘤患者预后评估中作用的临床研究[D]. 大连:大连医科大学,2020.
[26] Donati G, Zappulo F, Maietti E, et al. Early light chains removal and albumin levels with a double filter-based extracorporeal treatment for acute myeloma kidney[J].Toxins (Basel),2022,14(6):391.DOI:10.3390/toxins14060391.
[27] 香雪,柴晔,王鑫,等. sFLC/MP水平及轻链逃逸在多发性骨髓瘤复发患者中的临床意义[J]. 中国实验血液学杂志,2021,29(6):1837-1844.DOI:10.19746/j.cnki.issn1009-2137.2021.06.025.
[28] 李喆琪,田卫伟,郭雅芳,等. 血清游离轻链比值及治疗后比值正常化对初诊多发性骨髓瘤患者诊断及预后的影响[J]. 中国实验血液学杂志,2020,28(4):1245-1250.DOI:10.19746/j.cnki.issn1009-2137.2020.04.027.
[29] Banderker RB, Fazel FB, Zemlin AE, et al. Serum-free light chain test utilisation at a South African academic laboratory and comparison with serum protein electrophoresis results[J].Afr J Lab Med,2023,12(1):2201.DOI:10.4102/ajlm.v12i1.2201.
[30] Azimi V, Fiala MA, Zaydman MA. Use of the current standard of practice serum free light chains (sFLC) reference interval puts black patients at 5 times higher odds for light chain monoclonal gammopathy of undetermined significance (LC-MGUS)[J].Clin Chem,2023,69(9):1084-1086.DOI:10.1093/clinchem/hvad083.